Akebia Ther


Prices are adjusted according to historical splits.

Akebia Ther Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$181.65 million
Book Value:
Revenue TTM:
$297.03 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Akebia Ther had its IPO on 2014-03-20 under the ticker symbol AKBA.

The company operates in the Healthcare sector and Biotechnology industry. Akebia Ther has a staff strength of 426 employees.

Stock update

Shares of Akebia Ther opened at $0.6 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $0.55 - $0.61, and closed at $0.56.

This is a -6.91% slip from the previous day's closing price.

A total volume of 1,191,398 shares were traded at the close of the day’s session.

In the last one week, shares of Akebia Ther have slipped by -15.69%.

Akebia Ther's Key Ratios

Akebia Ther has a market cap of $181.65 million, indicating a price to book ratio of 4.1167 and a price to sales ratio of 0.2809.

In the last 12-months Akebia Ther’s revenue was $297.03 million with a gross profit of $-17922000 and an EBITDA of $-67984000. The EBITDA ratio measures Akebia Ther's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Akebia Ther’s operating margin was -35.59% while its return on assets stood at -12.73% with a return of equity of -206.21%.

In Q3, Akebia Ther’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0.4%.

Akebia Ther’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.9 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Akebia Ther’s profitability.

Akebia Ther stock is trading at a EV to sales ratio of 0.0443 and a EV to EBITDA ratio of -0.13. Its price to sales ratio in the trailing 12-months stood at 0.2809.

Akebia Ther stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$435.89 million
Total Liabilities
$187.97 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Akebia Ther ended 2023 with $435.89 million in total assets and $0 in total liabilities. Its intangible assets were valued at $435.89 million while shareholder equity stood at $13.85 million.

Akebia Ther ended 2023 with $0 in deferred long-term liabilities, $187.97 million in other current liabilities, 2000.00 in common stock, $-1545361000.00 in retained earnings and $55.05 million in goodwill. Its cash balance stood at $144.76 million and cash and short-term investments were $144.76 million. The company’s total short-term debt was $70,207,000 while long-term debt stood at $0.

Akebia Ther’s total current assets stands at $237.51 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $23.09 million compared to accounts payable of $19.71 million and inventory worth $40.04 million.

In 2023, Akebia Ther's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Akebia Ther paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Akebia Ther stock is currently trading at $0.56 per share. It touched a 52-week high of $2.86 and a 52-week low of $2.86. Analysts tracking the stock have a 12-month average target price of $1.63.

Its 50-day moving average was $0.79 and 200-day moving average was $0.48 The short ratio stood at 1.72 indicating a short percent outstanding of 0%.

Around 127.9% of the company’s stock are held by insiders while 2923% are held by institutions.

Frequently Asked Questions About Akebia Ther

The stock symbol (also called stock or share ticker) of Akebia Ther is AKBA

The IPO of Akebia Ther took place on 2014-03-20

Similar Industry Stocks (Biotechnology)

Last Price
Amyris Inc (AMRS)
Wise plc (WIZEY)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.


245 First Street, Cambridge, MA, United States, 02142